“活体药物”针对晚期肾肿瘤中的 CD70。
'Living drugs' target CD70 in advanced renal tumors.
发表日期：2024 Jul 29
作者：
Kilian Wagner, Peter J Siska
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES
摘要：
针对实体瘤的细胞疗法面临三大障碍：持久性低、特异性不足和成本高。在最近的一项研究中，Pal 等人。通过使用针对稳定抗原的新型“持久性调整”同种异体嵌合抗原受体 (CAR) T 细胞来应对肾癌中的这些挑战。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。
Cellular therapies against solid tumors face three major barriers: low persistence, insufficient specificity, and high costs. In a recent study, Pal et al. tackle these challenges in kidney cancer by using novel, 'persistence-tuned' allogeneic chimeric antigen receptor (CAR) T cells directed against a stable antigen.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.